4 research outputs found
Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning
Applied immunology; Predictive markers; Viral infectionImmunologia aplicada; Marcadors predictius; InfecciĂł viralInmunologĂa aplicada; Marcadores predictivos; InfecciĂłn viralQuantitative or qualitative differences in immunity may drive clinical severity in COVID-19. Although longitudinal studies to record the course of immunological changes are ample, they do not necessarily predict clinical progression at the time of hospital admission. Here we show, by a machine learning approach using serum pro-inflammatory, anti-inflammatory and anti-viral cytokine and anti-SARS-CoV-2 antibody measurements as input data, that COVID-19 patients cluster into three distinct immune phenotype groups. These immune-types, determined by unsupervised hierarchical clustering that is agnostic to severity, predict clinical course. The identified immune-types do not associate with disease duration at hospital admittance, but rather reflect variations in the nature and kinetics of individual patientâs immune response. Thus, our work provides an immune-type based scheme to stratify COVID-19 patients at hospital admittance into high and low risk clinical categories with distinct cytokine and antibody profiles that may guide personalized therapy.This work was supported by Health Holland LSHM20056 grant (PDK), in part from the European Unionâs Horizon 2020 research and innovation program under grant agreement No 779295 (PDK), in part supported by the Erasmus foundation (BJAR), grant PI20/00416 from the Instituto de Salud Carlos III (RPB) and the European Regional Development Fund (ERDF) (RPB)
Basophil Activation Test in the prediction of anaphylactic reactions against Hymenoptera venom in patients suffering from Systemic Mastocytosis
Basophil Activation Test in the prediction of anaphylactic reactions against Hymenoptera venom in patients suffering from Systemic Mastocytosis
Evaluation of Cladribine treatment in refractory celiac disease type II
AIM: To evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) II